1. At a Glance
Manbro Industries is that friend who promises to host a lavish buffet but serves only chai-biscuits. Incorporated in 1992, the company claims to be in food & beverages, pharma, healthcare, and packaging – basically, everything except rocket science. Yet, FY25 sales are a mere ₹0.73 Cr, while the company sports a market cap of ₹326 Cr. With a P/E of 216x and Price/Sales of 447x, Manbro isn’t selling food – it’s selling dreams at luxury prices.
2. Introduction
Manbro’s story is like a Bollywood script gone wrong:
- Started in the 90s, diversified into everything from snacks to syringes.
- Keeps reshuffling leadership like a game of musical chairs – two MDs quit within 18 months.
- Raises capital via preferential allotments but struggles to sell actual products.
The irony? Despite reporting negligible revenues, the company clocked ₹1.51 Cr PAT last year, thanks mostly to “other income.” Imagine running a restaurant where the rent deposit interest is more profitable than the food.
The market once priced the stock at ₹1,300 (52-week high), now it’s hanging around ₹562 – a 57% crash, yet still valued like a gourmet chef in a street food stall.
3. Business Model (WTF Do They Even Do?)
Manbro’s stated business objects could fill a Big Bazaar catalogue:
- Food & Beverages: Everything from pickles to pulses, juices to ice creams.
- Pharma & Healthcare: Antibiotics, ayurvedic supplements, surgical instruments, contraceptives (yes, even that).
- Packaging & Processing: Bottling, repacking, and pharma vialling.
But actual numbers expose the reality: Sales dropped 98% YoY, and operations seem more “paper products” than “physical products.” Related party transactions (₹13.2 Cr with Biovivid Labs, ₹9.4 Cr with Manbro Polymers) hint that business activity is largely intra-group shuffling.
